| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 07/28/2005 | US20050165118 Hypotensive agents; antiinflammatory agents; gastrointestinal disorders; autoimmune disease; 4-phenyl pinene derivatives |
| 07/28/2005 | US20050165117 Hyperforin derivatives, the use thereof and formulations containing them |
| 07/28/2005 | US20050165113 (3S)-N-butyl-3-((2S)-2-(((4-fluorophenyl)sulfonyl)amino)-3-methylbutanoylamino)-5-methyl-2-oxohexanamide; calpain inhibition; Alzheimer's, osteoporosis, brain and eye disorders, ischemia |
| 07/28/2005 | US20050165106 Preferentially inhibit the inducible isoform of nitric oxide synthase |
| 07/28/2005 | US20050165103 for enhancing the endogenous production of interleukin-10 (IL-10) and suppressing the production of interleukin-2 in mammalian cells or tissues; inhibiting the proliferation of stimulated peripheral mononuclear cells |
| 07/28/2005 | US20050165092 Crystalline base of citalopram |
| 07/28/2005 | US20050165087 Nf-kb inhibitors |
| 07/28/2005 | US20050165086 Aminothiophene inhibitors of NF- kappa B inhibitors for treatment of diseases such as cancer or aids |
| 07/28/2005 | US20050165080 Administering a selective imidazoline receptor agonist: moxonidine, rilmenidine, 1,4-diisopropyl-2-(4,5-dihydro-1H-imidazol-2-yl)-piperazine, 1-(4,5-dihydro-1H-imidazol-2-yl)-isoquinoline; treating osteoporosis and hypertension simultaneously; perimenopausal or postmenopausal female |
| 07/28/2005 | US20050165069 Statine derivatives for the treatment of Alzheimer's disease |
| 07/28/2005 | US20050165048 For prophylaxis and therapy of adverse conditions of the central nervous system, including anxiety, convulsions and cognitive disorders |
| 07/28/2005 | US20050165047 alpha 7 nicotinic acetylcholine receptor agonist; dissolving N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide to an alcohol, adding fumaric acid, precipitating salt out of the solution; neurodegenerative and psychological disorders |
| 07/28/2005 | US20050165036 Substituted benzofurans and benzothiophenes, methods of making and methods of use as integrin antagonists |
| 07/28/2005 | US20050165023 Imidazo-triazine derivatives as ligands for gaba receptors |
| 07/28/2005 | US20050165022 Dihydro-1,3,5-triazine amine derivatives and their therapeutic uses |
| 07/28/2005 | US20050165019 Propenecarboxylic acid amidoxime derivatives, a process for the preparation thereof, and pharmaceutical compositions containing the same |
| 07/28/2005 | US20050165017 Such as (3S)-2-[3-[(phenylacetyl)amino]-1-oxopropyl]-N-[cyano(3-phenoxyphenyl)methyl]hexahydro-3-pyridazinecarboxamide; for treatment of osteoporosis, hypercalcaemia, osteoporosis, gingival disease, arthritis, Paget's disease, and bone cancer |
| 07/28/2005 | US20050165016 Piperazinyl-, piperidinyl- and morpholinyl-derivatives as novel inhibitors of histone deacetylase |
| 07/28/2005 | US20050165011 6-[5-(6-methyl-pyridin-2-yl)-1H-[1,2,3]triazol-4-yl]-4H-benzo[1,4]oxazin-3-one, used as inhibitors of the transforming growth factor beta-signalling pathways, in particular, the phosphorylation of smad gene and proteins or activin-like kinase receptors; prophylaxis of kidney fibrosis |
| 07/28/2005 | US20050165009 Remedy for glioblastoma |
| 07/28/2005 | US20050165008 7-chloro-4-(2-fluoroethyl)-3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide; AMPA (alpha -amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid)modulators; antidepressant, anxiolytic agent |
| 07/28/2005 | US20050164995 Method of locking 1alpha-OH of vitamin D compounds in axial orientation |
| 07/28/2005 | US20050164988 Bisphosphate, bis-quaternary ammonium or bis-amine salt compounds that bind a Toll-like receptor; use desensitizing allergies, treating autoimmune diseases and inflammatory diseases, ischemia |
| 07/28/2005 | US20050164948 Methods of treatment with prosaposin-derived peptides |
| 07/28/2005 | US20050164925 Treatment of gastroparesis |
| 07/28/2005 | US20050164917 Methods and means for producing proteins with predetermined post-translational modifications |
| 07/28/2005 | US20050164307 Methods of screening agonistic antibody |
| 07/28/2005 | US20050164305 Diagnostics and therapeutics for diseases associated with n-formyl peptide receptor like 1 (fprl1) |
| 07/28/2005 | US20050164298 Diagnostics and therapeutics for diseases associated with growth hormone secretagogue receptor(ghs) |
| 07/28/2005 | US20050164233 Compositions, kits and methods for identification and modulation of type I diabetes |
| 07/28/2005 | US20050164201 Isolated nucleic acid molecule encoding a novel centromere-associated motor protein, and uses therof |
| 07/28/2005 | US20050164185 Interferon receptor variant for treatment and prevention of cell proliferative, autoimmune and viral diseases; prolonged activation of interferon beta |
| 07/28/2005 | US20050163879 Composition for preventing or treating dementia comprising a hydroxycinnamic acid derivative or an extract of a plant of genus Angelicae containing same |
| 07/28/2005 | US20050163809 Remedy for hypermyotonia |
| 07/28/2005 | US20050163788 Prevention and treatment of amyloidogenic disease |
| 07/28/2005 | US20050163786 Compounds and methods for modulating adhesion molecule function |
| 07/28/2005 | US20050163778 Extracorporeal photopheresis in combination with anti-TNF treatment |
| 07/28/2005 | US20050163760 sustained delivery of a molecule to the central nervous system; bioavailability; population of cells enriched in hematopoietic stem or progenitor or stem cells capable of migrating to the CNS upon administration |
| 07/28/2005 | US20050163752 Human interferon-beta formulations |
| 07/28/2005 | US20050163751 Synergistic mixture with compounds such as interferon, paclitaxel or P-16; side effect reduction |
| 07/28/2005 | US20050163744 Novel method for down-regulation of amyloid |
| 07/28/2005 | US20050163719 Buccal, polar and non-polar spray containing diazepam |
| 07/28/2005 | DE10359384A1 Verwendung eines Extraktes von Aloysia triphylla als Matrixprotektor Use of an extract of Aloysia triphylla as a matrix protector |
| 07/28/2005 | DE10043321B4 Verwendung eines transdermalen therapeutischen Systems zur Behandlung der Parkinsonschen Krankheit, zur Behandlung und Prävention des prämenstruellen Syndroms und zur Lactationshemmung Use of a transdermal therapeutic system for the treatment of Parkinson's disease, for the treatment and prevention of premenstrual syndrome and Lactationshemmung |
| 07/28/2005 | CA2554382A1 Compounds useful in therapy |
| 07/28/2005 | CA2553938A1 Diaza-spiropiperidine derivatives as inhibitors of glycine transporter 1 and glycine transporter 2 |
| 07/28/2005 | CA2553329A1 New fused polycyclic compounds |
| 07/28/2005 | CA2553200A1 6-amino-5-cyano-pyrimidine-4-ones used for improving perception, power of concentration, learning efficiency, and/or memory power |
| 07/28/2005 | CA2552965A1 Carboxamide derivative and use thereof |
| 07/28/2005 | CA2552681A1 1-benzyl-5-piperazin-1-yl-3,4 dihydro-1h-quinazolin-2-one derivatives and the respective 1h-benzo(1,2,6)thiadiazine-2,2-dioxide and 1,4-dihydro-benzo(d) (1,3)oxazin-2-one derivatives as modulators of the 5-hydroxytryptamine receptor (5-ht) for the treatment of diseases of the central nervous system |
| 07/28/2005 | CA2552471A1 Combination of crf antagonists and 5-ht 1b receptor antagonists |
| 07/28/2005 | CA2551689A1 Memantine for the treatment of mild and mild-to-moderate alzheimer's disease |
| 07/28/2005 | CA2548982A1 A process for the preparation of 4-(2-dipropylaminoethyl)-1,3-dihydro-2h-indol-2-one hydrochloride |
| 07/27/2005 | EP1557430A1 Antibody and utilization of the same |
| 07/27/2005 | EP1557428A1 Antibodies against a human stromal derived factor (SDF) and pharmaceutical composition containing them |
| 07/27/2005 | EP1557427A2 Hedgehog protein conjugate |
| 07/27/2005 | EP1557417A1 Substituted 8'-pyri(mi)dinyl-dihydrospiro-[cycloalkylamine]-pyrimido[1,2a] pyrimidin-6-one derivatives |
| 07/27/2005 | EP1557414A1 Isoquinoline compounds and medicinal use thereof |
| 07/27/2005 | EP1557412A1 Fluorinated benzothiadiazine derivatives and their use as AMPA receptor modulators |
| 07/27/2005 | EP1557409A1 5HT2C receptor modulators |
| 07/27/2005 | EP1557407A1 Novel alpha-ketoamide derivative and use thereof |
| 07/27/2005 | EP1557174A1 Composition containing eosinophil cationic protein |
| 07/27/2005 | EP1557171A1 Rabbit skin comprising biological active substance and its use |
| 07/27/2005 | EP1556705A2 Diagnostics and therapeutics for diseases associated with human g-protein coupled receptor 14 (gpr14) |
| 07/27/2005 | EP1556489A1 Pharmaceutical composition for preparing a medicine for treating and/or preventing a pathology related to an obsessive behaviour or obesity |
| 07/27/2005 | EP1556401A2 22 human secreted proteins |
| 07/27/2005 | EP1556378A1 Acyl derivatives of 5-(2-(4-(1,2 benzisothiazole-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one having neuroleptic activity |
| 07/27/2005 | EP1556369A1 Pyridazinone-derivatives as pde4 inhibitors |
| 07/27/2005 | EP1556355A1 Inhibitors of glycogen synthase kinase 3 |
| 07/27/2005 | EP1556354A2 Therapeutic piperazine derivates useful for treating pain |
| 07/27/2005 | EP1556353A1 Diaryl compounds as monoamine reuptake inhibitors |
| 07/27/2005 | EP1556352A1 Compounds capable of activating cholinergic receptors |
| 07/27/2005 | EP1556351A1 Secondary amino anilinic piperidines as mch1 antagonists and uses thereof |
| 07/27/2005 | EP1556347A2 Gamma lactams as prostaglandin agonists and use thereof |
| 07/27/2005 | EP1556333A1 Hydroxyphenylundecane derivates, a process for their production and their use |
| 07/27/2005 | EP1556330A2 Phenyl compounds |
| 07/27/2005 | EP1556080A1 Use of convertase inhibitors in the treatment of fibrosis and scarring |
| 07/27/2005 | EP1556068A2 Treatment of autism and similar disorders |
| 07/27/2005 | EP1556066A2 Compositions and methods of use for a fibroblast growth factor |
| 07/27/2005 | EP1556062A2 Herbal extract comprising a mixture of saponins obtained from sapindus trifoliatus for anticonvulsant activity |
| 07/27/2005 | EP1556055A2 Use of cyclic nucleotide phosphodiesterase inhibitors having a benzodiazepine structure in therapy |
| 07/27/2005 | EP1556054A1 Antagonizing nk1 receptors inhibits consumption of substances of abuse |
| 07/27/2005 | EP1556046A1 Phenylpiperidines and phenylpyrrolidines as histamine h3 receptor modulators |
| 07/27/2005 | EP1556045A1 4-aminopiperidine derivatives, processes for their preparation and their use as medicaments |
| 07/27/2005 | EP1556038A2 Acetophenone potentiators of metabotropic glutamate receptors |
| 07/27/2005 | EP1556037A1 4-piperazinyl benzenesulfonyl indoles with 5-ht6 receptor affinity |
| 07/27/2005 | EP1556033A1 Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases |
| 07/27/2005 | EP1556028A1 Eicosapentaenoic acid (epa) for treating anorexia nervosa (an) and bulimia |
| 07/27/2005 | EP1556019A2 Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors |
| 07/27/2005 | EP1556004A2 Pharmaceutical compositions for buccal delivery of pain relief medications |
| 07/27/2005 | EP1379523B1 1,2,3,4-tetrahydroisoquinolines derivatives as urotensin ii receptor antagonists |
| 07/27/2005 | EP1377573B1 Pyrazolopyridine derivatives |
| 07/27/2005 | EP1351961B1 Substituted indolines as 5-ht receptor ligands |
| 07/27/2005 | EP1339711B1 Aminothiazoles and their use as adenosine receptor antagonists |
| 07/27/2005 | EP1318992B1 Imidazole derivatives as raf kinase inhibitors |
| 07/27/2005 | EP1315723B1 The hydrochloride salt of 5[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione |
| 07/27/2005 | EP1296665A4 Analgesic and anti-inflammatory compositions containing cox-2 inhibitors |
| 07/27/2005 | EP1289559B1 Combinations of enzyme inhibitor-containing preparations and the use thereof |
| 07/27/2005 | EP1283823A4 Novel mmp-2/mmp-9 inhibitors |
| 07/27/2005 | EP1274411B1 Phenylethylamines and condensed rings variants as prodrugs of catecholamines, and their use |